CME
Meeting Future Global Challenges: Case-Based Presentations in the Management of NSCLC
June 15, 2021
Host: Paul Paik, MD
Guest: Joshua K. Sabari, MD
For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!